pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
JOHNSON & JOHNSON ($JNJ) · news · pharmadog
← back to JOHNSON & JOHNSON
News mentioning $JNJ
106
stories
1d
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
fiercebiotech
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
3d
Johnson & Johnson MedTech nabs Monarch Quest 3 update for lung cancer detection
fiercebiotech
4d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
4d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
4d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
7d
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
7d
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
7d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board
endpoints
8d
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
8d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
8d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
10d
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
11d
BMS picks Texas for new $2.3B manufacturing campus
biospace
11d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
11d
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
11d
Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub
fiercebiotech
14d
Jennifer Taubert announces retirement from J&J; Takeda's global TYK2 leader exits
endpoints
14d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
15d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
17d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
18d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
22d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
22d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
← prev
page 1 of 4
next →
